Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5769402 | 0.93 | CA12 (0.44) | CA1CA2RETCA12CA7 | |
| SCHEMBL5768982 | 0.87 | ALDH2 (0.42) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5946257 | 0.83 | MAPT (0.47) | KDM4ERETNPC1LMNAMAPT | |
| SCHEMBL5772174 | 0.82 | SLC6A3 (0.53) | ESR2CYP1A2BACE1HDAC4HDAC2 | |
| SCHEMBL28080955 | 0.78 | IDO1 (0.46) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5768977 | 0.77 | PRMT3 (0.38) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6370434 | 0.74 | HTR3A (0.47) | — | |
| SCHEMBL20746534 | 0.74 | SLC6A4 (0.42) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL28680034 | 0.73 | PTGS2 (0.46) | KDM4ENPC1RAB9A | |
| SCHEMBL29071892 | 0.71 | HTT (0.73) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | PHARMA MAR, S.A.U. (ES) | 2006-12-21 | — | — | US | disclosed |
| EP-1613635-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004073598-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A.U. (ES) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | TSNAX, TSN, PLIN5 | ESR2 4173/4885KDM4E 2697/4885CYP1A2 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.